BLOOMFIELD, Conn., Feb. 3, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE: CI) today announced a new multi-year effort aimed at meaningfully transforming the experiences of the millions of people it serves.
"The health care system in America needs to be better, and we have challenged ourselves to help lead and drive systemic change," said David M. Cordani, chairman and CEO of The Cigna Group. "We do a lot of good for many people, but we need to do better for everyone. We are committed to implementing tangible actions across our company to help drive better health outcomes and health care experiences. Today's announcement marks the initial steps in our multi-year journey toward building a better and more sustainable model in health care."
The Cigna Group has established five key areas of focus, and several initial specific actions, to improve the health of its customers and the value it provides:
Initial Actions To Drive The Cigna Group's Commitments
The Cigna Group: To ensure alignment in priorities and greater accountability, The Cigna Group will tie its leaders' compensation to improving the satisfaction of its customers.
Additionally, starting in early 2026, The Cigna Group will publish an annual Customer Transparency Report to make its progress toward its commitments clear. The report will include important information relating to how the company facilitates customer care, including details about its services and resolution statistics.
Cigna Healthcare: As announced separately today, Cigna Healthcare is taking the following actions:
Evernorth Health Services: Evernorth recently announced actions to address Express Scripts' patient access and affordability and improve transparency.
Going forward, Evernorth's standard offerings will protect patients from paying the high list price of their medications, ensuring they benefit from the lower price negotiated by Express Scripts. Additionally, patients in employer-sponsored plans will have improved financial predictability, receiving the benefit of savings negotiated by Express Scripts if they don't already.
As part of this broader effort, the company also committed to providing an annual personalized summary to customers about how they benefit directly from the discounted prices Express Scripts negotiates and providing an annual standardized report to plan sponsors disclosing costs and pharmacy claim-level reporting.
Executive Changes To Ensure Accountability
The Cigna Group's work to drive significant improvements for all its customers will be governed by its new Office of Excellence and Transformation. This office will partner across the organization to shape the company's response to improve the health of the millions of customers it serves and to ensure accountability.
The office will have oversight by Dr. David Brailer, the company's executive vice president and chief health officer and a highly experienced physician. Additionally, Chris DeRosa will assume a newly created role leading the office, reporting to Dr. Brailer. DeRosa, a longtime Cigna Healthcare leader with a deep understanding of the needs of customers and health plan sponsors, currently serves as president, U.S. Government, Cigna Healthcare. DeRosa will continue to oversee the company's Medicare businesses through the transaction with HCSC, which we expect will close in the first quarter.
"I am inspired to work alongside our 70,000 colleagues and the Office of Excellence and Transformation to realize our commitments to better care and clinical excellence," Dr. Brailer said. "We will lead the health care industry in how we serve our patients and customers and support the clinicians who care for them."
More information about The Cigna Group's commitments is available here.
About The Cigna Group
The Cigna Group (NYSE: CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Cigna Healthcare, Evernorth Health Services, or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 markets and jurisdictions and has approximately 182 million customer relationships around the world. Learn more at thecignagroup.com.
Media Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$311.99 |
Daily Change: | 0.94 0.30 |
Daily Volume: | 1,372,629 |
Market Cap: | US$86.780B |
January 30, 2025 October 31, 2024 September 12, 2024 September 12, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load